VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Papadimitrakopoulou on Role of Immunotherapy in Lung Cancer

Vassiliki A. Papadimitrakopoulou, MD
Published: Friday, Feb 03, 2017



Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

Patients with lung cancer who have a high expression of PD-L1—in more than 50% of cells—are found to benefit from PD-L1 monotherapy. It is not certain whether this is the best way to indicate eligibility for immunotherapy.

Although, with the recent approval of pembrolizumab (Keytruda), this subset of patients should also be considered for upfront immunotherapy, says Papadimitrakopoulou.
 


Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

Patients with lung cancer who have a high expression of PD-L1—in more than 50% of cells—are found to benefit from PD-L1 monotherapy. It is not certain whether this is the best way to indicate eligibility for immunotherapy.

Although, with the recent approval of pembrolizumab (Keytruda), this subset of patients should also be considered for upfront immunotherapy, says Papadimitrakopoulou.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x